Edition:
India

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

26.50USD
1:30am IST
Change (% chg)

$1.65 (+6.64%)
Prev Close
$24.85
Open
$26.00
Day's High
$27.14
Day's Low
$25.84
Volume
83,226
Avg. Vol
82,899
52-wk High
$40.60
52-wk Low
$15.20

Select another date:

Fri, Sep 7 2018

Akcea Therapeutics to cut about 10 percent of workforce

Akcea Therapeutics Inc said on Thursday it planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve its Waylivra drug for treating a genetic disease that causes fat accumulation in blood.

UPDATE 1-Akcea Therapeutics to cut about 10 pct of workforce

Sept 6 Akcea Therapeutics Inc said on Thursday it planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve its Waylivra drug for treating a genetic disease that causes fat accumulation in blood.

Akcea Therapeutics to cut about 10 pct of workforce

Sept 6 Akcea Therapeutics Inc said on Thursday it planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve its Waylivra drug for treating a genetic disease that causes fat accumulation in blood.

FDA declines to approve Akcea-Ionis genetic disease drug

The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease that causes fat accumulation in the blood.

U.S. FDA declines to approve Akcea/Ionis genetic disease drug

Aug 27 The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease which causes fat accumulation in the blood.

Select another date: